Screener
Novavax NVAX Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $22,936 | $24,578 |
| Accrued expenses | 81,424 | 107,165 |
| Deferred revenue | 86,577 | 140,053 |
| Current portion of finance lease liabilities | 4,110 | 2,507 |
| Other current liabilities | 135,527 | 137,778 |
| Liabilities held for sale | — | 47,869 |
| Total current liabilities | 330,574 | 459,950 |
| Deferred revenue | 356,755 | 358,943 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's current debt?
- Novavax (NVAX) reported current debt of $4.11M in Q2 2026.
- How has Novavax's current debt changed year-over-year?
- Novavax's current debt decreased by 26.0% year-over-year, from $5.55M to $4.11M.
- What is the long-term trend for Novavax's current debt?
- Over 5 years (2020 to 2025), Novavax's current debt has grown at a -52.7% compound annual growth rate (CAGR), from $105.86M to $2.51M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Novavax's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude